Business & Finance
BioNTech expects EUR17bn in revenues from COVID-19 vaccine in 2021
9 November 2021 -

Germany biotechnology company s BioNTech SE (Nasdaq:BNTX) has said that the COVID-19 vaccine, developed with partner Pfizer (NYSE:PFE), is likely to generate up to EUR17bn in revenues this year, Reuters news agency reported on Tuesday.

This comes as booster shots are being planned and the use in children increases.

BioNTech said in a statement that based on planned deliveries of up to 2.5 billion doses so far, it expects EUR16bn to EUR17bn in revenues accruing to it from the vaccine this year. This is an increase over the prior forecast in August 2021 of EUR15.9bn.

The revenues includes milestone payments from partners and a share of gross profit in its partners' territories, BioNTech added.